Lapatinib Activates the Kelch-Like ECH-Associated Protein 1-Nuclear Factor Erythroid 2-Related Factor 2 Pathway in HepG2 Cells

The uricosuric benzbromarone disturbs the mitochondrial redox homeostasis and activates the NRF2 signaling pathway in HepG2 cells

(2020) Noëmi Johanna Roos et al.   FREE RADICAL BIOLOGY AND MEDICINE

Molecular Mechanism of Cellular Oxidative Stress Sensing by Keap1

(2019) Takafumi Suzuki et al.   Cell Reports

The KEAP1-NRF2 System: a Thiol-Based Sensor-Effector Apparatus for Maintaining Redox Homeostasis

(2018) Masayuki Yamamoto et al.   PHYSIOLOGICAL REVIEWS

Characterisation of the HLA-DRB1*07:01 biomarker for lapatinib-induced liver toxicity during treatment of early-stage breast cancer patients with lapatinib in combination with trastuzumab and/or taxanes

(2017) C F Spraggs et al.   PHARMACOGENOMICS JOURNAL

Hepatocellular Toxicity Associated with Tyrosine Kinase Inhibitors: Mitochondrial Damage and Inhibition of Glycolysis

(2017) Franziska Paech et al.   Frontiers in Pharmacology

P450 3A-Catalyzed O-Dealkylation of Lapatinib Induces Mitochondrial Stress and Activates Nrf2

(2016) Marsha Rebecca Eno et al.   CHEMICAL RESEARCH IN TOXICOLOGY

Mitochondrial generation of superoxide and hydrogen peroxide as the source of mitochondrial redox signaling

(2016) Martin D. Brand   FREE RADICAL BIOLOGY AND MEDICINE

Comparison of Liver Cell Models Using the Basel Phenotyping Cocktail

(2016) Benjamin Berger et al.   Frontiers in Pharmacology

Mitochondrial Reactive Oxygen Species (ROS) and ROS-Induced ROS Release

(2014) Dmitry B. Zorov et al.   PHYSIOLOGICAL REVIEWS

Pattern of Rash, Diarrhea, and Hepatic Toxicities Secondary to Lapatinib and Their Association With Age and Response to Neoadjuvant Therapy: Analysis From the NeoALTTO Trial

(2013) Hatem A. Azim et al.   JOURNAL OF CLINICAL ONCOLOGY

Analysis of GSH and GSSG after derivatization with N-ethylmaleimide

(2013) Daniela Giustarini et al.   Nature Protocols

Time series analysis of oxidative stress response patterns in HepG2: A toxicogenomics approach

(2013) L. Deferme et al.   TOXICOLOGY

Characterization of primary human hepatocytes, HepG2 cells, and HepaRG cells at the mRNA level and CYP activity in response to inducers and their predictivity for the detection of human hepatotoxins

(2012) H. H. J. Gerets et al.   CELL BIOLOGY AND TOXICOLOGY

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial

(2012) José Baselga et al.   LANCET

Mechanisms of Hepatocellular Toxicity Associated with Dronedarone—A Comparison to Amiodarone

(2012) Andrea Felser et al.   TOXICOLOGICAL SCIENCES

Polyphenols activate Nrf2 in astrocytes via H2O2, semiquinones, and quinones

(2011) Hilla Erlank et al.   FREE RADICAL BIOLOGY AND MEDICINE

Oncogenic Targets, Magnitude of Benefit, and Market Pricing of Antineoplastic Drugs

(2011) Eitan Amir et al.   JOURNAL OF CLINICAL ONCOLOGY

HLA-DQA1*02:01 Is a Major Risk Factor for Lapatinib-Induced Hepatotoxicity in Women With Advanced Breast Cancer

(2011) Colin F. Spraggs et al.   JOURNAL OF CLINICAL ONCOLOGY

Lapatinib-induced hepatitis: A case report

(2011) Stavros Peroukides   WORLD JOURNAL OF GASTROENTEROLOGY

The sites and topology of mitochondrial superoxide production

(2010) Martin D. Brand   EXPERIMENTAL GERONTOLOGY

Mechanism-Based Inactivation of Cytochrome P450 3A4 by Lapatinib

(2010) W. C. Teng et al.   MOLECULAR PHARMACOLOGY

Isolation of functional pure mitochondria by superparamagnetic microbeads

(2009) Hue-Tran Hornig-Do et al.   ANALYTICAL BIOCHEMISTRY

Effects of Food on the Relative Bioavailability of Lapatinib in Cancer Patients

(2009) Kevin M. Koch et al.   JOURNAL OF CLINICAL ONCOLOGY

Increased Nrf2 Activation in Livers from Keap1-Knockdown Mice Increases Expression of Cytoprotective Genes that Detoxify Electrophiles more than those that Detoxify Reactive Oxygen Species

(2009) Scott A. Reisman et al.   TOXICOLOGICAL SCIENCES

Lapatinib: A dual inhibitor of human epidermal growth factor receptor tyrosine kinases

(2008) P MEDINA et al.   CLINICAL THERAPEUTICS

Efficacy and Safety of Lapatinib As First-Line Therapy for ErbB2-Amplified Locally Advanced or Metastatic Breast Cancer

(2008) Henry L. Gomez et al.   JOURNAL OF CLINICAL ONCOLOGY

FDA Drug Approval Summary: Lapatinib in Combination with Capecitabine for Previously Treated Metastatic Breast Cancer That Overexpresses HER-2

(2008) Q. Ryan et al.   ONCOLOGIST